Tarsus Pharmaceuticals Acquires Alkeus Pharmaceuticals
August 6, 2026
Tarsus Pharmaceuticals agreed to acquire Alkeus Pharmaceuticals for approximately $450 million upfront—$270 million in cash and $180 million in Tarsus stock—with up to $350 million in milestone payments and tiered royalties. Tarsus completed the acquisition on September 4, 2026, adding worldwide rights to Alkeus’s Phase 3 Stargardt disease therapy, gildeuretinol (ALK-001), to expand its retina pipeline and eye-care portfolio.
- Buyers
- Tarsus Pharmaceuticals, Inc.
- Targets
- Alkeus Pharmaceuticals, Inc.
- Sellers
- Alkeus stockholders
- Industry
- Biotechnology
- Location
- Massachusetts, United States
- Transaction Type
- Buyout
Explore More
Build a buyer list for your deal
Find active buyers from recent acquisition patterns and move straight into outreach.